The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Recruitment of adults with fragile X syndrome to test NM-1001, a microdose of the psychedelic psilocybin is ongoing in Ontario, Canada.| Fragile X News Today
Children with fragile X syndrome have had problems with their academic performance and social interactions since the COVID-19 pandemic.| Fragile X News Today
Category archive page for News.| Fragile X News Today
Marisa Wexler is a senior science writer for Fragile X News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
A combination of ibudilast and gaboxadol was shown to normalize behavior and improve memory in a mouse model of fragile X syndrome.| Fragile X News Today
Fragile X-causing mutations in FMR1 cause structural DNA changes that affect other genes necessary for nerve cell function, a study says.| Fragile X News Today
